Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide for multiple sclerosis.

L La Mantia1, C Milanese, N Mascoli

  • 1MS Group, Istituto Nazionale Neurologico C. Besta, Via Celoria, 11, MIlano, Italy, 20133. msgroup@istituto-besta.it

The Cochrane Database of Systematic Reviews
|January 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel approaches for understanding and improving the effectiveness of seed biopriming.

Scientific reports·2026
Same author

Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial.

ESMO open·2025
Same author

Corrigendum to [Effects of a new compound containing Palmitoylethanolamide and Baicalein in myocardial ischaemia/reperfusion injury in vivo] [PHYMED: 2019 Feb 15;54:27-42 Epub 2018 Sep 19].

Phytomedicine : international journal of phytotherapy and phytopharmacology·2023
Same author

Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2022
Same author

Impact of sarcopenia in SARS-CoV-2 patients during two different epidemic waves.

Clinical nutrition ESPEN·2022
Same author

Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Cyclophosphamide (CFX) did not prevent long-term disability progression in progressive multiple sclerosis (MS). However, it showed a significant benefit in slowing disability at 12 and 18 months, though side effects were frequent.

Area of Science:

  • Neuroimmunology
  • Clinical Pharmacology
  • Systematic Reviews

Background:

  • Multiple sclerosis (MS) is an autoimmune central nervous system disorder.
  • Cyclophosphamide (CFX) is an immunosuppressive drug with debated efficacy in MS.
  • This review evaluates CFX's effectiveness in progressive MS.

Purpose of the Study:

  • To determine if cyclophosphamide (CFX) slows disease progression in progressive multiple sclerosis (MS).

Main Methods:

  • Systematic search of electronic databases (MEDLINE, EMBASE, Cochrane) and conference abstracts.
  • Included randomized controlled trials (RCTs) of CFX in progressive MS, alone or with steroids, versus placebo or no treatment.
  • Assessed disability progression (Kurtzke EDSS) and side effects.

Related Experiment Videos

Main Results:

  • Four RCTs (152 participants) were analyzed.
  • CFX did not prevent long-term disability progression (EDSS) at 12-24 months.
  • CFX significantly favored the treated group in mean disability change at 12 and 18 months.
  • Frequent side effects included sepsis and amenorrhea; five deaths occurred.

Conclusions:

  • CFX shows a potential role in progressive MS treatment.
  • Less toxic administration schedules are needed for clinical use.
  • Further research into optimized CFX regimens is warranted.